Last updated 2026-07-20
- Acquired by Medivie Therapeutic, Apr 2014
- Raised Undisclosed Round led by Coronis Partners, Dec 1969
Total raised
—
Last: Undisclosed Round
Stage
Acquired
Founded
1999
Headcount
31
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences
About
Glycominds International is an innovative diagnostics company that develops and commercializes gastrointestinal disease management tools and services. Their GI dry serum testing helps physicians identify patients with Celiac Disease and Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis) for early, non-invasive, accurate, and cost-effective diagnosis. They also predict Crohn's Disease patients at higher risk for complicated disease and monitor Anti-TNF therapy. Glycominds also develops tests to identify multiple sclerosis and its severity. Glycominds is a leading groundbreaker in microbiome biomarker research, offering validated serum biomarker tests for Inflammatory Bowel Disease.
Funding history · 1 round · — total
1969-12
Undisclosed Round
Undisclosed
★ Coronis Partners
Q&A
- What is Glycominds' primary business?
- Glycominds is a molecular diagnostics company that develops and commercializes gastrointestinal disease management tools and services, focusing on Celiac Disease and Inflammatory Bowel Diseases.
- When was Glycominds founded?
- Glycominds was founded in January 1999.
- What is the current status of Glycominds?
- Glycominds was acquired by Medivie Therapeutic in April 2014 and is currently inactive.
- Who acquired Glycominds and when?
- Glycominds was acquired by Medivie Therapeutic in April 2014.
- Where was Glycominds headquartered?
- Glycominds was headquartered in Modi'in-Maccabim-Re'ut, Israel.
- Who are the co-founders of Glycominds?
- The co-founders of Glycominds are Nir Dotan and Avi (Avinoam) Dukler, Ph.D.
- What types of diseases did Glycominds' diagnostic tools target?
- Glycominds' diagnostic tools targeted Celiac Disease and Inflammatory Bowel Diseases, including Crohn's Disease and Ulcerative Colitis.
Team · 2
Avi Dukler
Founder · Co-Founder & CEO
Nir Dotan
Founder · Co-Founder & CTO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesMedical Devices IndustryMedical Equipment
Business model
B2B
Tags
chronic-deseasescrohn-s-diseasepharmaceuticalsceliac-diseaseautoimmune-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | glycominds.com/ |
|---|
Identifiers & details
| Founded | 1999-1 |
|---|---|
| Employees (exact) | 31 |
| Offices | Simi Valley |
| Status reason | Acquired (Inactive) by Medivie Therapeutic on Apr 2014 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Medivie Therapeutic 2014-04
Radar intelligence
Patents
| EPO | 17 |
|---|
Publications (Crossref)
| Works | 6 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515175867 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-01-19 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | התדהר 16 רעננה |
Recent registry events
| Date | Event |
|---|---|
| 2026-03-18 | דו~ח שנתי |